Share Price:

APNASPENAspen Pharmacare Hldgs21701-219 (-1.00%)
Our Response to Covid
Country Sites

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform to be released on 4 March 2024.

Regional Overviews

Aspen in Africa Middle East

The Africa Middle East region comprises 45 countries and ranks as the second-largest revenue contributor by region in the Group. Its commercial and sales teams support both local and international brands, each with robust brand equity, within the Commercial Pharmaceuticals segment, which contributes 22% of total revenue.


One of the Group‘s strategic manufacturing sites is located in Gqeberha, South Africa, and has extensive capabilities in high-potency and hormonal solids, vaccines, and advanced sterile technologies. South Africa also hosts two additional regional manufacturing sites in Cape Town and East London, while further sites in Ghana, Kenya, and Tanzania all contribute to the region’s manufacturing strength.

Key Countries

Egypt
Kingdom of Saudi Arabia
South Africa
Tanzania
Kenya

Overview

Learn More
Brand Therapeutic category

Imuran

Immunosuppressant

Mara Moja

Analgesic anti-inflammatory

Mybulen

Analgesic anti-inflammatory

Stilpane

Narcotic analgesic combinations

Trustan

Anti-ulcerant
10
Products
Launched

(2022: 25)

0
Product
Recalls

(2022: 1)

0 %
Average Staff
Turnover

(2022: 13%)

Work-related
Facilities

(2022: Nil)

100
Sales
Representatives

(2022: 218)

2500
Permanent
Employees

(June 2022: 3,945)

Revenue 2023
R’million		 2022 (CER)
R’million		 Change
%

Commercial Pharmaceuticals

8 154

8 523

(4)

Regional Brands

7 711

7 983

(3)

Sterile Focus Brands

443

540

18

Manufacturing

646

2 051

>100

API Chemicals

192

229

(16)

FDF - Other

11

22

(50)

FDF - Steriles

443

1 800

(75)
Total

8 800

10 574

(17)

Note: Commercial Pharmaceuticals revenue is by customer geography and manufacturing revenue by place of manufacture.

Contribution to Group revenue (%)
  • Rest of Group 78
  • Africa Middle East 22
Revenue by segment (%)
  • Regional Brands 88
  • Manufacturing - FDF 5
  • Sterile Focus Brands 5
  • Manufacturing - API Chemicals 2
  • The South African private pharmaceutical sector was valued at R54,5 billion MAT# for the period ended June 2023.
  • Aspen has the second highest market share by value within the South African private sector, at 9,4%.
  • By 2025, Middle East & Africa pharmaceutical market is collectively estimated to be USD56 billion, with United Arab Emirates and Egypt contributing 24,0% and 17,4% respectively.
  • Middle East, North Africa & Turkey pharmaceutical market is expected to grow by 4,6% compound annual growth rate from 2021 to 2024, driven mainly by Turkey and Egypt.

Source: IQVIA June 2023. Sources: IQVIA TPM Moving Annual Total June 2022, IQVIA Middle East & Africa Pharmaceutical Market Insights. Released June 2022.
* Moving annual total (“MAT”).

Our Purpose

Find out more
To improve the health and quality of life of patients.

Our Vision

Find out more
To deliver value to all our stakeholders as a responsible corporate citizen that provides high-quality, affordable medicines globally.

Our Values

Find out more
Define the foundation on which Aspen has been built. These are the values we share as we work together toward achieving the vision of the Group.
aspen-holdings-logo-white-img

Aspen Holdings
www.aspenpharma.com
Hotline (South Africa)
0800 122 912

Medical Careline (South Africa) 0800 118 088

Facebook-f Twitter-square Instagram Linkedin

About Aspen

We Care

Careers

Contact Us

ASPEN PHARMACARE HOLDINGS LTD:
Switchboard: +27 31 580-8600

Aspen Place
9 Rydall Vale Park
Douglas Saunders Drive
La Lucia Ridge
South Africa

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.